Their genome analysis platform has already been described as potentially, or even likely, best-in-class by several independent reviews and experts. However, the company apparently isn't good at marketing bc adoption has really underperformed expectations. It's kind of risky buying off of this PR since ER is tmrw. It's AH tmrw, so at least that gives some time for a bit of a run if volume continues. But the PR itself isn't anything that's too exciting: they've released maybe dozens of these announcements already to no avail.
Disclaimer: The comments, opinions and analysis expressed herein are for informational and educational purposes only and shoulk not be considered as individual investment advice or recommendations. Webull is not responsible or liable in any way for comments posted by pur users.
Download the Webull App and join community for discussions about the post. Download
What everyone average? Im in at 46, holding 500 shares Vhk 12/04/2020 02:27
i have been waiting a very long time for this day 😅cal***com 12/03/2020 23:44